Critical Diagnostics, a U.S.-based biomarker
company focused on cardiovascular diseases, today announced the appointment of
three distributors in China, Korea and Indonesia for its Presage ST2 Assay.
The
company further stated that it anticipates adding several more Asia Pacific
distributors in the coming months.
"The
Asia Pacific region is an essential component in our overall business strategy
to develop a worldwide presence for our Presage ST2 Assay," says David
Geliebter, Chairman of Critical Diagnostics. "We see tremendous potential
for growth in that part of the world. Teaming up with highly-regarded local
partners is key to that approach."
The
Presage ST2 Assay quantitatively measures the level of ST2 in blood. ST2 has
been shown to be a significant predictor of mortality as well as all-cause
hospitalization, mortality due to cardiovascular disease, and hospitalization
due to cardiovascular disease. ST2 is prognostic for clinically important
outcomes in addition to all-cause mortality. Levels of ST2 are independent and
complimentary to natriuretic peptide markers and not adversely affected by such
confounding factors as age, gender, body mass index and impaired renal
function.
Critical
Diagnostics has chosen Everbest, a division of RIPI Group, as exclusive
distributor in the Peoples Republic of China, Hong Kong, Macau and Taiwan. RIPI
Group specializes in the IVD market. RIPI Group's major business partners
include Ortho Clinical Diagnostics (a division of Johnson & Johnson, USA),
as well as several Asia Pacific-based medical companies. Headquartered in
Shanghai, Everbest also has offices in Hong Kong, Beijing and Taipei.
Jinbiotech
has been selected to act as exclusive distributor in the Republic of Korea. The
company has long-term relationships with leaders in the cardiology community.
Based in Nowon, South Korea, Jinbiotech was established in 2001 by founder and President,
Charlie Song, who has over 25 years of experience in the IVD industry in Korea.
Mr. Song was formerly President for Baxter Korean Inc.
In
Indonesia, Critical Diagnostics has designated Tri Surya Medika as its
exclusive distributor. The principals of Tri Surya Medika are highly
experienced in the IVD market and have worked with such companies as Novartis
Vaccines & Diagnostics, Tecan, Echosens, Alere, and ICU Medical.
Headquartered in Jakarta, Tri Surya Medika has eight regional offices and more than
30 strategic sub-distributor partners.
"We're
very pleased to be partnering with these three fine organizations," notes
James Snider, President of Critical Diagnostics. "They bring a wealth of
experience and contacts in their respective markets, and we look forward to
many years of active cooperation."
Overseeing
Asia Pacific sales for the company will be John A. Butterfield, Vice President
for Business Development, Asia Pacific. Prior to joining Critical Diagnostics
John spent over 10 years in commercial business development of clinical
biomarkers in the region, most recently representing Alere, formerly Inverness
Medical, as the Director of Clinical Cardiovascular/Renal Asia Pacific. John
holds a B.App.Sc (Honours) in Sport and Exercise Science from University of
Western Sydney, also, MBA from La Trobe University in Melbourne, and is
currently researching cardiovascular biomarkers in cardiac disease patients at
the University of Western Sydney's Ph.D. program.
About
Critical Diagnostics and ST2
Critical
Diagnostics ( www.criticaldiagnostics.com ) develops novel biomarkers to help
physicians optimize patient care in cardiovascular diseases, while containing
healthcare costs. The Presage(R) ST2 Assay has been CE Marked and cleared by
the US FDA. Critical Diagnostics has exclusive worldwide rights to ST2 for the
diagnosis and prognosis of cardiovascular disease.
SOURCE:
Critical Diagnostics
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.
No comments:
Post a Comment